EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Plasma Biomarkers Differentiate Cognitive Impairment in Postmenopausal Women with Insomnia Disorder

Danyun Wang iD, Bing Chen iD, Kangyu Jin iD, Shangping Cheng iD, Bin Qin iD, Yuting Tian iD, Jing Lu iD, Ketan Chu iD

Psychiatry and Clinical Psychopharmacology · 12.08.2026 · 36 (4) · 338-360

DOI: 10.65801/pcp.3463 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Psychiatry and Clinical Psychopharmacology, online erschienen am 12.08.2026. Verfasst von Danyun Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sleep disorders are common in postmenopausal women and may contribute to cognitive decline. We investigated whether plasma biomarkers differentiate cognitive impairment (CI) in this population.

Methods

In this cross-sectional exploratory study, we recruited 105 outpatients with insomnia disorder (79 women and 26 men) aged 45-60 years with insomnia symptoms (PSQI > 5, ISI > 7). Cognition was assessed using the Chinese Brief Cognitive Test (CBCT) and Auditory Verbal Learning Test. Postmenopausal women were classified as CI or non-CI based on CBCT criteria. Plasma glial fibrillary acidic protein (GFAP), neurofilament light chain, orexin A, total tau, and phosphorylated tau-181 (p-Tau) were measured using enzyme-linked immunosorbent assay. Associations with cognition and exploratory classification performance were examined using correlation and receiver operating characteristic analyses.

Results

Postmenopausal women exhibited higher anxiety and poorer cognitive performance despite comparable insomnia severity. Among them (non-CI n=42; CI n=37), the CI group had higher plasma GFAP (14.82 vs. 12.42 ng/mL, P = .004) and p-Tau (1,002.18 vs. 918.27 pg/mL, P = .034). Biomarkercognition correlations were weak. GFAP showed the highest apparent performance among individual biomarkers (area under the curve, AUC = 0.672). The clinical information-adjusted model incorporating orexin A, GFAP, and p-Tau showed the highest apparent AUC among biomarker combinations (AUC = 0.755), although internally validated performance was more modest.

Conclusions

Plasma GFAP and p-Tau, with potential incremental contribution from orexin A, may provide exploratory information for identifying cognitive vulnerability in postmenopausal women with insomnia disorder. These exploratory findings require validation in larger and independent cohorts.

Schlagwörter

Stichwörter der Autor:innen

GFAPcognitive impairmentinsomnia disorderneurofilament light chainphosphorylated taupostmenopause

Autor:innen und Institutionen

  • Department of Gynecology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.
  • Department of Psychiatry, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
  • Zhejiang Key Laboratory of Precision Psychiatry, Hangzhou, China.

ORCID-Profile: Danyun Wang, Bing Chen, Kangyu Jin, Shangping Cheng, Bin Qin, Yuting Tian, Jing Lu, Ketan Chu

Zitieren

APA

Wang, D., Chen, B., Jin, K., Cheng, S., Qin, B., Tian, Y., Lu, J., & Chu, K. (2026). Plasma Biomarkers Differentiate Cognitive Impairment in Postmenopausal Women with Insomnia Disorder. Psychiatry and Clinical Psychopharmacology, 36(4), 338-360. https://doi.org/10.65801/pcp.3463

Vancouver

Wang D, Chen B, Jin K, Cheng S, Qin B, Tian Y, et al. Plasma Biomarkers Differentiate Cognitive Impairment in Postmenopausal Women with Insomnia Disorder. Psychiatry and Clinical Psychopharmacology. 2026;36(4):338-360. doi:10.65801/pcp.3463

BibTeX
@article{Wang2026,
  author = {Wang, Danyun and Chen, Bing and Jin, Kangyu and Cheng, Shangping and Qin, Bin and Tian, Yuting and Lu, Jing and Chu, Ketan},
  title = {Plasma Biomarkers Differentiate Cognitive Impairment in Postmenopausal Women with Insomnia Disorder},
  journal = {Psychiatry and Clinical Psychopharmacology},
  year = {2026},
  volume = {36},
  number = {4},
  pages = {338--360},
  doi = {10.65801/pcp.3463}
}
Kostenlos starten →